Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers.

Andrea Tinelli, Raffaele Prudenzano, Antonio Malvasi, Mario Santantonio, Vito Lorusso

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Advanced cases of uterine carcinomas with parametrial and fornix infiltration often cause massive genital bleeding, with severe anemia, fast deterioration, and a high risk of death for patients; women with advanced uterine cancer (UC) and genital massive bleeding were treated using an endovascular therapy in local anesthesia. Ten women with advanced UC and genital massive bleeding were hospitalized for a high risk of immediate death; after blood transfusions and resuscitation therapy, the patients were submitted to an experimental nanopharmacologic endovascular therapy in local anesthesia. On average, the total operative time for the procedure was 38.6 minutes, the intrasurgical blood loss was of 37 mL, the postoperative analgesic request for 48 hours was just for 3 patients (all dismissed in the second day after pelvic artery embolization), the hemoglobin level at dismissal was of 6.5 g/L, and the duration of hospital stay was 1.4 days. All patients well tolerated the procedure, with no linked complications; clinical check was at the 10th and 30th days after dismissal, with no further recurrent genital bleeding in the follow-up course stopped at the visit in the 60th day. Genital bleeding in advanced UC is a serious complication because it causes deterioration of the patient's general status and has a worse prognosis. The pelvic uterine embolization according to our endovascular nanopharmacologic methods is bloodless, less traumatic, and faster than a surgical procedure. Even if it requires experience in intervention radiology, it enables the continuation of external radiotherapy without delay and can replace laparotomic or laparoscopic treatment.

Original languageEnglish
Pages (from-to)1250-1255
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume20
Issue number7
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Emergencies
Uterine Neoplasms
Hemorrhage
Local Anesthesia
Neoplasms
Therapeutics
Operative Surgical Procedures
Operative Time
Radiology
Resuscitation
Blood Transfusion
Analgesics
Anemia
Length of Stay
Hemoglobins
Radiotherapy
Arteries
Carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers. / Tinelli, Andrea; Prudenzano, Raffaele; Malvasi, Antonio; Santantonio, Mario; Lorusso, Vito.

In: International Journal of Gynecological Cancer, Vol. 20, No. 7, 10.2010, p. 1250-1255.

Research output: Contribution to journalArticle

Tinelli, Andrea ; Prudenzano, Raffaele ; Malvasi, Antonio ; Santantonio, Mario ; Lorusso, Vito. / Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers. In: International Journal of Gynecological Cancer. 2010 ; Vol. 20, No. 7. pp. 1250-1255.
@article{1ae86c75283b45a9af4c9de616c7acfe,
title = "Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers.",
abstract = "Advanced cases of uterine carcinomas with parametrial and fornix infiltration often cause massive genital bleeding, with severe anemia, fast deterioration, and a high risk of death for patients; women with advanced uterine cancer (UC) and genital massive bleeding were treated using an endovascular therapy in local anesthesia. Ten women with advanced UC and genital massive bleeding were hospitalized for a high risk of immediate death; after blood transfusions and resuscitation therapy, the patients were submitted to an experimental nanopharmacologic endovascular therapy in local anesthesia. On average, the total operative time for the procedure was 38.6 minutes, the intrasurgical blood loss was of 37 mL, the postoperative analgesic request for 48 hours was just for 3 patients (all dismissed in the second day after pelvic artery embolization), the hemoglobin level at dismissal was of 6.5 g/L, and the duration of hospital stay was 1.4 days. All patients well tolerated the procedure, with no linked complications; clinical check was at the 10th and 30th days after dismissal, with no further recurrent genital bleeding in the follow-up course stopped at the visit in the 60th day. Genital bleeding in advanced UC is a serious complication because it causes deterioration of the patient's general status and has a worse prognosis. The pelvic uterine embolization according to our endovascular nanopharmacologic methods is bloodless, less traumatic, and faster than a surgical procedure. Even if it requires experience in intervention radiology, it enables the continuation of external radiotherapy without delay and can replace laparotomic or laparoscopic treatment.",
author = "Andrea Tinelli and Raffaele Prudenzano and Antonio Malvasi and Mario Santantonio and Vito Lorusso",
year = "2010",
month = "10",
doi = "10.1111/IGC.0b013e3181e4a68d",
language = "English",
volume = "20",
pages = "1250--1255",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers.

AU - Tinelli, Andrea

AU - Prudenzano, Raffaele

AU - Malvasi, Antonio

AU - Santantonio, Mario

AU - Lorusso, Vito

PY - 2010/10

Y1 - 2010/10

N2 - Advanced cases of uterine carcinomas with parametrial and fornix infiltration often cause massive genital bleeding, with severe anemia, fast deterioration, and a high risk of death for patients; women with advanced uterine cancer (UC) and genital massive bleeding were treated using an endovascular therapy in local anesthesia. Ten women with advanced UC and genital massive bleeding were hospitalized for a high risk of immediate death; after blood transfusions and resuscitation therapy, the patients were submitted to an experimental nanopharmacologic endovascular therapy in local anesthesia. On average, the total operative time for the procedure was 38.6 minutes, the intrasurgical blood loss was of 37 mL, the postoperative analgesic request for 48 hours was just for 3 patients (all dismissed in the second day after pelvic artery embolization), the hemoglobin level at dismissal was of 6.5 g/L, and the duration of hospital stay was 1.4 days. All patients well tolerated the procedure, with no linked complications; clinical check was at the 10th and 30th days after dismissal, with no further recurrent genital bleeding in the follow-up course stopped at the visit in the 60th day. Genital bleeding in advanced UC is a serious complication because it causes deterioration of the patient's general status and has a worse prognosis. The pelvic uterine embolization according to our endovascular nanopharmacologic methods is bloodless, less traumatic, and faster than a surgical procedure. Even if it requires experience in intervention radiology, it enables the continuation of external radiotherapy without delay and can replace laparotomic or laparoscopic treatment.

AB - Advanced cases of uterine carcinomas with parametrial and fornix infiltration often cause massive genital bleeding, with severe anemia, fast deterioration, and a high risk of death for patients; women with advanced uterine cancer (UC) and genital massive bleeding were treated using an endovascular therapy in local anesthesia. Ten women with advanced UC and genital massive bleeding were hospitalized for a high risk of immediate death; after blood transfusions and resuscitation therapy, the patients were submitted to an experimental nanopharmacologic endovascular therapy in local anesthesia. On average, the total operative time for the procedure was 38.6 minutes, the intrasurgical blood loss was of 37 mL, the postoperative analgesic request for 48 hours was just for 3 patients (all dismissed in the second day after pelvic artery embolization), the hemoglobin level at dismissal was of 6.5 g/L, and the duration of hospital stay was 1.4 days. All patients well tolerated the procedure, with no linked complications; clinical check was at the 10th and 30th days after dismissal, with no further recurrent genital bleeding in the follow-up course stopped at the visit in the 60th day. Genital bleeding in advanced UC is a serious complication because it causes deterioration of the patient's general status and has a worse prognosis. The pelvic uterine embolization according to our endovascular nanopharmacologic methods is bloodless, less traumatic, and faster than a surgical procedure. Even if it requires experience in intervention radiology, it enables the continuation of external radiotherapy without delay and can replace laparotomic or laparoscopic treatment.

UR - http://www.scopus.com/inward/record.url?scp=79960670928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960670928&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181e4a68d

DO - 10.1111/IGC.0b013e3181e4a68d

M3 - Article

VL - 20

SP - 1250

EP - 1255

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 7

ER -